SecBot SecBot

ACLX

Arcellx, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001786205 Biotech & Drug Discovery
No price
Median target
$115.00
range $82.00–120.00
Insider net
$0
no open-market trades · since Apr 28
New fund stakes
0
Q2 2026 13F · 34 exits
Filing reports
3
analyzed by SecBot
SecBot read BEARISH 3 reports · latest
Balance 2 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Apr 28. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 34 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.101 → −$1.019 over 90 days. 3 up, 0 down in 30 days.

Who's buying

13F· Q2 2026
0
new positions
34
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Feb 2026
Recent actions
DateFirmActionRating
Feb 26, 2026Guggenheim
DOWNGRADE
DOWNGRADENeutral
Feb 24, 2026Truist Securities
DOWNGRADE
DOWNGRADEHold
Feb 24, 2026Evercore ISI Group
DOWNGRADE
DOWNGRADEIn-Line
Feb 24, 2026UBS
DOWNGRADE
DOWNGRADENeutral
Feb 24, 2026Citigroup
DOWNGRADE
DOWNGRADENeutral
Feb 24, 2026Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform

Insider ledger

Form 4
$0
open-market buys or sells · since Apr 28
DateInsiderTypeValue
Apr 28, 2026
Heery Christopher
CHIEF MEDICAL OFFICER
Apr 28, 2026
TO ISSUER45,138 sh
Apr 28, 2026
Ware Olivia C
Director
Apr 28, 2026
TO ISSUER36,806 sh
Apr 28, 2026
Gilson Michelle
CHIEF FINANCIAL OFFICER
Apr 28, 2026
TO ISSUER20,496 sh
Apr 28, 2026
Patel Kavita
Director
Apr 28, 2026
TO ISSUER20,513 sh
Apr 28, 2026
Heery Christopher
CHIEF MEDICAL OFFICER
Apr 28, 2026
TO ISSUER40,000 sh
Apr 28, 2026
Heery Christopher
CHIEF MEDICAL OFFICER
Apr 28, 2026
TO ISSUER76,242 sh
Apr 28, 2026
Patel Kavita
Director
Apr 28, 2026
TO ISSUER11,459 sh
Apr 28, 2026
Heery Christopher
CHIEF MEDICAL OFFICER
Apr 28, 2026
TO ISSUER60,096 sh

Earnings setup

Estimates
−$1.02
EPS estimate, this quarter
+7%
estimate change, 90 days
3↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.02-$1.11–-$0.95-0.1%$6.8M
Next FY-$1.48-$4.47–$1.95+14.5%$274.3M
Next Q-$1.06-$1.19–-$0.96+0.0%$7.8M
Current FY-$4.22-$4.77–-$3.85+0.0%$68.8M
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Aug 5, 2026 Earnings calendar
ACLX Q2 2026 Earnings After Market Close, 2026-08-05
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO · EXIT
0 shares ($0.00)
Apr 28, 2026 SEC
Arcellx, Inc. (ACLX) has been involuntarily delisted from Nasdaq, with the exchange filing a Form 25-NSE to remove the…
25-NSE · Impact 9/10
Apr 28, 2026 Insider
Heery Christopher disposed of 45,138 shares
CHIEF MEDICAL OFFICER
Apr 28, 2026 Insider
Ware Olivia C disposed of 36,806 shares
Director
Apr 28, 2026 Insider
Gilson Michelle disposed of 20,496 shares
CHIEF FINANCIAL OFFICER
Apr 24, 2026 SEC
Arcellx filed an amended 10-K/A to include Part III disclosures (director and executive compensation, ownership, and…
10-K/A · Impact 2/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

3 filings · 0 bullish · 2 bearish · 1 neutral
All ACLX filing & press-release reports (3)